B+
Bull case
20%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
FBIO
Fortress BiotechANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Fortress has a diversified portfolio spanning commercial products, royalties, equity interests, and development-stage programs. Q2 revenue growth, expanded Emrosi access, launched-product royalties, and partnered-program progress support a positive but speculative setup [#SEC-8K-2026-08-13].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +10.1.
What can break
Clinical and regulatory outcomes for partnered programs, including anselamimab and dotinurad, remain uncertain.
Momentum
91
Value
70
Sentiment
87
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.20 · Bull $5.00 · Bear $1.50Analysis 2026-09-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.00
Why
Momentum91 · Δ7d +0.4
Value70 · Δ7d 0.0
Sentiment87 · Δ7d +10.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +10.1.
Contradictions & invalidation
- • Clinical and regulatory outcomes for partnered programs, including anselamimab and dotinurad, remain uncertain.
- • Emrosi payer access expansion may not translate proportionally into prescriptions or sustained revenue growth.
- • The pipeline remains dependent on partner execution, regulatory progress, commercialization, and royalty realization.
Catalyst clock
2026-12-08
Royalty realization from launched products
Lead driver: Sentiment · See AI snapshot
Momentum
91
9% active weight
Current posture
7d trendImproving
Δ7d
+0.4
Δ21d
+20.6
Value
70
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.2
Sentiment
87
62% active weight
Current posture
7d trendImproving
Δ7d
+10.1
Δ21d
-7.5
Why this grade
Composite grade A. Momentum 91.4 / Value 69.9 / Sentiment 87.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-09. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$93.68M
Beta
1.44
Shares Out
33.22M
P/E (TTM) · Derived
-41.8
P/S (TTM)
2.13
P/FCF (TTM) · Derived
1.06
Rev YoY
+14.0%
EPS YoY
-117.4%
Gross Margin
+58.9%
Op Margin
-42.9%
Net Debt
-$12.17M
Current Ratio
3.96
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data